Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results

Legend Biotech (NASDAQ: LEGN) will host an investor conference call at 8:00 am ET on Tuesday, March 10, 2026 to review fourth-quarter and full-year 2025 results.

Rhea-AI Summary

Legend Biotech (NASDAQ: LEGN) will host an investor conference call at 8:00 am ET on Tuesday, March 10, 2026 to review fourth-quarter and full-year 2025 results. The call includes a live audio webcast and a replay plus the earnings release available in Investor Relations approximately two hours after the call.

Investors can access the live webcast via the company link; management will provide an overview of quarterly and full-year financial performance.

Argus Feb 24 session

-1.27% close to close Open Argus

Details

News Market Reaction – LEGN

In the Feb 24 session, LEGN declined 1.27%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement schedules Legend Biotech’s investor call to review Q4 and full-year 2025 results, ...

Analysis

This announcement schedules Legend Biotech’s investor call to review Q4 and full-year 2025 results, continuing its pattern of pre‑announcing quarterly earnings discussions with replay access a few hours later. In recent quarters, similar notices produced only modest share moves, while the stock has traded below its 200‑day MA of $30.33 and well under the $45.30 52‑week high. Investors may focus on how reported CARVYKTI sales, margins, and cash trends align with the profitability milestones highlighted in recent filings.

Key Figures

Conference call time: 8:00 am ET Conference call date: March 10, 2026 Replay availability delay: Approximately two hours

Conference call time

8:00 am ET

Investor call to review Q4 and full-year 2025 results on Mar 10, 2026

Conference call date

March 10, 2026

Scheduled date for discussing Q4 and full-year 2025 results

Replay availability delay

Approximately two hours

Time after call when webcast replay and earnings release are posted

Previous Conferences,earnings Reports

5 past events · Latest: Oct 29

Same Type 5 events

1. Oct 29

   Earnings call notice

   24h Move

   -1.4%

   Announced date and access details for Q3 2025 results call.

2. Jul 28

   Earnings call notice

   24h Move

   -4.3%

   Scheduled Q2 2025 earnings conference call and webcast logistics.

3. Apr 29

   Earnings call notice

   24h Move

   -0.8%

   Outlined timing and replay plan for Q1 2025 results call.

4. Feb 25

   Earnings call notice

   24h Move

   +0.1%

   Set schedule for Q4 and full-year 2024 earnings discussion.

5. Oct 24

   Earnings call notice

   24h Move

   +0.3%

   Announced Q3 2024 earnings call timing and webcast access.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOMERSET, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March 10, 2026, to review fourth-quarter and full-year 2025 financial results.

During the conference call and accompanying webcast, senior management will provide an overview of quarterly and full-year financial performance.

Investors and other interested parties may access the live audio webcast via this weblink.

A replay of the webcast, along with the earnings press release, will be available in the Investor Relations section of the Legend Biotech website under Events and Presentation approximately two hours after the conclusion of the call.

ABOUT LEGEND BIOTECH

With over 2,900 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI^®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

Learn more at www.legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.

INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
jessie.yeung@legendbiotech.com

PRESS CONTACT:
Kim Fox
Tel: (848) 388-8445
media@legendbiotech.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Legend Biotech's (LEGN) conference call for Q4 and full-year 2025 results?

The conference call is scheduled for 8:00 am ET on Tuesday, March 10, 2026. According to the company, senior management will review fourth-quarter and full-year 2025 financial results and provide an overview of performance during the webcast and call.

How can investors access the Legend Biotech (LEGN) live webcast for the March 10, 2026 call?

Investors can access the live audio webcast via the company's investor relations weblink. According to the company, the webcast link will be available on Legend Biotech's website and accessible to investors and interested parties.

When will the replay and earnings press release for Legend Biotech (LEGN) be available after the March 10, 2026 call?

A replay and the earnings press release will be available about two hours after the call concludes. According to the company, both items will be posted in the Investor Relations section under Events and Presentation.

What will Legend Biotech (LEGN) management cover during the March 10, 2026 investor call?

Management will provide an overview of the company's quarterly and full-year 2025 financial performance. According to the company, senior leaders will discuss results and context during the live webcast and take investor-focused topics.